Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

Palma, D. A., Olson, R. A., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C. J. A., Mulroy, L. A., Lock, M. I., Rodrigues, G., Yaremko, B., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,879

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Cohen, E. E. W., Soulières, D., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,737

Using immunotherapy to boost the abscopal effect

Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

Theelen, W. S. M. E., Peulen, H. M. U., Lalezari, F., van der Noort, V., de Vries, J. F., Aerts, J. G. J. V., Dumoulin, D. W., Bahce, I., Niemeijer, A.-L. N., de Langen, A. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1478 · Cited by 1,020

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928

Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?

Link, B., Crigna, A. T., Hölzel, M., Giordano, F. A., & Golubnitschaja, O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215124 · Cited by 27

Immunotherapy in Head and Neck Cancer When, How, and Why?

Pereira, D., Martins, D. F., & Mendes, F. (2022) · Biomedicines · doi:10.3390/biomedicines10092151 · Cited by 26

Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer

Rao, Y. J., Goodman, J., Haroun, F., & Bauman, J. E. (2023) · Cancers · doi:10.3390/cancers15030672 · Cited by 30

Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer

Wang, P., Yin, T., Zhao, K., Yu, J., & Teng, F. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03849-3 · Cited by 25

Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization

Jagodinsky, J. C., Bates, A. M., Clark, P. A., Sriramaneni, R. N., Havighurst, T. C., Chakravarty, I., Nystuen, E. J., Kim, K., Sondel, P. M., Jin, W. J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005103 · Cited by 25

The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers

Mestiri, S., El-Ella, D. M. A., Fernandes, Q., Bedhiafi, T., Almoghrabi, S., Akbar, S., Inchakalody, V. P., Assami, L., Anwar, S., Shahab Uddin, M. S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116095 · Cited by 28

The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges

Zhou, Z., Huang, S., Fan, F., Xu, Y., Moore, C., Li, S., & Han, C. (2024) · Medical Review · doi:10.1515/mr-2023-0061 · Cited by 25

A Review of Immunotherapy for Head and Neck Cancer

Goetz, J. W., Rabinowits, G., Kalman, N. S., & Villa, A. (2024) · Journal of Dental Research · doi:10.1177/00220345241271992 · Cited by 26

Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Babiker, H. M., Braña, I., Mahadevan, D., Owonikoko, T. K., Calvo, E., Rischin, D., Moreno, V., Papadopoulos, K. P., Crittenden, M. R., Formenti, S. C., et al. (2021) · The Oncologist · doi:10.1002/onco.13810 · Cited by 24

Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

Ni, J., Zhou, Y., Wu, L., Ai, X., Dong, X., Chu, Q., Han, C., Wang, X., & Zhu, Z. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01905-3 · Cited by 25

Oligometastatic Disease Management: Finding the Sweet Spot

Szturz, P., Nevens, D., & Vermorken, J. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.617793 · Cited by 23

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

Kazandjian, D. G., Dew, A., Hill, E., Ramirez, E. M. G., Morrison, C., Mena, E., Lindenberg, L., Yuan, C. M., Marić, I., Wang, H., et al. (2021) · The Oncologist · doi:10.1002/onco.13712 · Cited by 23

Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors

Huang, Z., Zheng, S., Ding, S., Wei, Y., Chen, C., Liu, X., Li, H., & Xia, Y. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1606_20 · Cited by 23

Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy

Liu, Y., Li, J., Xu, C., & Zhang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.795568 · Cited by 23

Low-dose irradiation for reversing immunotherapy resistance: how to translate?

Ochoa-de-Olza, M., Bourhis, J., Coukos, G., & Herrera, F. G. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004939 · Cited by 23

Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy

Kiasari, B. A., Abbasi, A., Darestani, N. G., Adabi, N., Moradian, A., Yazdani, Y., Hosseini, G. S., Gholami, N., & Janati, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109365 · Cited by 26

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

Kang, D., Liu, S.-P., Yuan, X., Liu, S.-X., Zhang, Z.-R., He, Z.-M., Yin, X.-D., & Mao, H.-Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05504-5 · Cited by 20

Mechanistic rationales for combining immunotherapy with radiotherapy

Chi, A., & Nguyen, N. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125905 · Cited by 25

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

Patin, E. C., Nenclares, P., Hak, C. C. W., Dillon, M. T., Patrikeev, A., McLaughlin, M., Grove, L., Foo, S., Soliman, H., Barata, J. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51236-6 · Cited by 22

ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors

van Aken, E. S. M., Devnani, B., Prelaj, A., Castelo-Branco, L., Marijnen, C. A. M., Martins-Branco, D. A., Gambacorta, M. A., Lamarca, Á., Harrington, K. J., Minniti, G. C., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.09.008 · Cited by 23

Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study

Shen, P. F., Qiao, B., Jin, N., & Wang, S. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01293-9 · Cited by 22

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Kim, H., Park, S., Jung, H. A., Lee, S., Park, K., Ahn, Y. C., Oh, D., & Ahn, M. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.502 · Cited by 22

A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma

Zhou, C., Li, Y., Li, J., Song, B., Li, H., Liang, B., Gu, S., Li, H., Chen, C., Li, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0410 · Cited by 22

Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives

Pannunzio, S., Bello, A. D., Occhipinti, D., Scala, A., Messina, G., Valente, G., Quirino, M., Salvatore, M. D., Tortora, G., & Cassano, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288695 · Cited by 22

Advances in nanotechnology-based approaches for the treatment of head and neck squamous cell carcinoma

Tang, B., Huang, R., & Wen-juan, M. (2024) · RSC Advances · doi:10.1039/d4ra07193j · Cited by 22

Oligometastasis in Head and Neck Squamous Cell Carcinoma

Moon, D. H., & Sher, D. J. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.06.086 · Cited by 21

Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

Gao, J., Zhang, X., Yang, Z., Zhang, J., Bai, Z., Deng, W., Chen, G., Xu, R. C., Wei, Q., Liu, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1057947 · Cited by 21

Modulation of CD8+ T Cell Responses by Radiotherapy—Current Evidence and Rationale for Combination with Immune Checkpoint Inhibitors

Jeon, S. H., Song, C., Eom, K., Kim, I. A., & Js, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316691 · Cited by 21

Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study

Fuereder, T., Minichsdorfer, C., Mittlboeck, M., Wagner, C., Heller, G., Putz, E. M., Oberndorfer, F., Müllauer, L., Aretin, M., Czerny, C., et al. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105634 · Cited by 21

Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer

Zafra, J., Onieva, J. L., Oliver, J., Garrido-Barros, M., González-Hernández, A., Martínez-Gálvez, B., Roman, A., Marmolejo, R. O., Pérez-Ruiz, E., Benítez, J. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084533 · Cited by 20

Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities

Saddawi‐Konefka, R., Simon, A. B., Sumner, W., Sharabi, A. B., Mell, L. K., & Cohen, E. E. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.738626 · Cited by 22

Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer

Ji, X., Zhao, Y., He, C., Han, S., Zhu, X., Shen, Z., Chen, C. Y., & Chu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659987 · Cited by 19

Immunotherapy in head and neck squamous cell carcinoma: a narrative review

Sharon, S., & Bell, R. B. (2021) · Frontiers of Oral and Maxillofacial Medicine · doi:10.21037/fomm-21-48 · Cited by 18

A Predictive Biophysical Model of the Combined Action of Radiation Therapy and Immunotherapy of Cancer

Friedrich, T., Scholz, M., & Durante, M. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.03.030 · Cited by 20

Construction of a novel disulfidptosis-related lncRNAs signature for prognosis prediction and anti-tumor immunity in laryngeal squamous cell carcinoma

Zhang, M., Sun, Q., Han, Z., Qin, X., Gao, T., Xu, Y., Han, S., Zhang, Y., Liang, Q., Guo, Z., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30877 · Cited by 19

Overcoming Resistance to Immunotherapy in Head and Neck Cancer Using Radiation: A Review

Hui, C., Chau, B., Gan, G., Stokes, W., Karam, S., & Amini, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.592319 · Cited by 14

Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy

Passelli, K., Repáraz, D., Kinj, R., & Herrera, F. G. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae100 · Cited by 18

Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer

Mulvey, A., Muggeo-Bertin, E., Berthold, D., & Herrera, F. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859785 · Cited by 18

The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Guévelou, J. L., Sargos, P., Siva, S., Ploussard, G., Ost, P., Gillessen, S., & Zilli, T. (2022) · European Urology Focus · doi:10.1016/j.euf.2022.08.016 · Cited by 18

Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon—A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Sequence

Mireștean, C. C., Iancu, R. I., & Iancu, D. T. (2022) · Current Oncology · doi:10.3390/curroncol29100580 · Cited by 19

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy

Shi, Y., Ma, X.-Y., He, D., Dong, B., & Qiao, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213222 · Cited by 20

NK cells propagate T cell immunity following in situ tumor vaccination

Jin, W. J., Jagodinsky, J. C., Vera, J. M., Clark, P. A., Zuleger, C., Erbe, A. K., Ong, I. M., Lе, T., Tetreault, K., Berg, T. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113556 · Cited by 21

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies

Swami, U., Chennamadhavuni, A., Borcherding, N. C., Bossler, A., Mott, S. L., Garje, R., Zakharia, Y., & Milhem, M. M. (2020) · Antibiotics · doi:10.3390/antibiotics9110740 · Cited by 18

Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy

Wang, X., & Jing, J. (2025) · MedComm · doi:10.1002/mco2.70346 · Cited by 21

Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR )

Gill, S., Nowak, A. K., Bowyer, S. E., Endersby, R., Ebert, M. A., & Cook, A. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13441 · Cited by 17

ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control

Blair, T. C., Baird, J. R., Bambina, S., Kramer, G. F., Gostissa, M., Harvey, C. J., Gough, M. J., & Crittenden, M. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-19256-8 · Cited by 20

Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites

Martin, A. L., Powell, C. D., Nagy, M. Z., Innamarato, P., Powers, J. J., Nichols, D. A., Anadon, C. M., Chaurio, R. A., Kim, S., Wang, M.-H., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03325-y · Cited by 16

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Corbacho, J. G., Indacochea, A., González‐Navarro, E. A., Ruiz, I. V., Moreno, D., Pesántez, D., Angelats, L., Modrego-Sánchez, A., Sanfeliu, E., Castillo, O., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03360-9 · Cited by 18

Killing two birds with one stone: Abscopal effect mechanism and its application prospect in radiotherapy

Yu, B., Gao, Y., Li, J., Gao, F., Zhang, J., Li, L., Feng, X., Zuo, D., Jin, X., Chen, W., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104325 · Cited by 17

Genomic predictors of radiation response: recent progress towards personalized radiotherapy for brain metastases

Harary, P. M., Rajaram, S., Chen, M. S., Hori, Y. S., Park, D. J., & Chang, S. D. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02270-2 · Cited by 20

The head and neck cancer genome in the era of immunotherapy

Wijetunga, N. A., Yu, Y., Morris, L. G. T., Lee, N. Y., & Riaz, N. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105040 · Cited by 17

Future Directions in the Use of SAbR for the Treatment of Oligometastatic Cancers

Morris, Z. S., Dohopolski, M. J., Rahimi, A. S., & Timmerman, R. D. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.03.004 · Cited by 18

The Role of Stereotactic Body Radiation Therapy in the Management of Liver Metastases

Lee, S. L., Bassetti, M. F., & Rusthoven, C. G. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2022.11.008 · Cited by 16

Management of oligometastatic head and neck squamous cell carcinoma: A systematic review

Lehyanti, J., Even, C., Fessart, E., Wagner-Ballon, C., Moreira, A., & Houessinon, A. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.107085 · Cited by 17

Combining the past and present to advance immuno-radiotherapy of cancer

Koukourakis, I. M., & Koukourakis, M. I. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1974020 · Cited by 16

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors

Ji, X., Jiang, W., Wang, J., Zhou, B., Ding, W., Liu, S., Huang, H., Chen, G., & Sun, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1106644 · Cited by 18

Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review

Tamimi, A., Tamimi, A., Sorkheh, F., Asl, S. M., Ghafari, A., Karimi, A. G., Erabi, G., Pourmontaseri, H., & Deravi, N. (2023) · Cancer Reports · doi:10.1002/cnr2.1802 · Cited by 16

Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience

Sarı, S. Y., Yılmaz, M. T., Aktaş, B. Y., Aksoy, S., Güllü, İ., Cengiz, M., Özyiğit, G., & Yazıcı, G. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105658 · Cited by 15

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review

Zhang, Y., Yao, Q., Pan, Y., Fang, X., Xu, H., Zhao, T., Zhu, G., Jiang, T., Li, S., & Cao, H. (2023) · Cancers · doi:10.3390/cancers15030682 · Cited by 18

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors

Schubert, P., Rutzner, S., Eckstein, M., Frey, B., Schweizer, C., Haderlein, M., Lettmaier, S., Semrau, S., Gostian, A., Zhou, J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576643 · Cited by 17

Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play

Donlon, N. E., Power, R. F., Hayes, C., Davern, M., Reynolds, J. V., & Lysaght, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031071 · Cited by 15

Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions

David, S., Tan, J., Siva, S., Karroum, L., Savas, P. S., & Loi, S. (2022) · Biomedicines · doi:10.3390/biomedicines10040821 · Cited by 15

Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade

Mahmood, U., Huynh, M. A., Killoran, J. H., Qian, J. M., Bent, E. H., Aizer, A. A., Mak, R. H., Mamon, H. J., Balboni, T. A., Gunasti, L., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.008 · Cited by 15

Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)

Seligmann, J. F., Koessler, T., Mauer, M. E. L., Évrard, S., Freedman, J., Gootjes, E. C., Gückenberger, M., Govaerts, A.-S., Giraut, A., Ricke, J., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105508 · Cited by 16

Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Patel, R., Saab, K., Luo, L., Ma, Y., Osman, R. A., Williams, N. T., Everitt, J. I., Żelazowski, M. J., Castro, P. D., Decker, W. K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0112 · Cited by 14

The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer

Sharon, S., Daher-Ghanem, N., Zaid, D., Gough, M. J., & Kravchenko‐Balasha, N. (2023) · Frontiers in Oral Health · doi:10.3389/froh.2023.1180869 · Cited by 16

Recurrent Versus Metastatic Head and Neck Cancer: An Evolving Landscape and the Role of Immunotherapy

Belfiore, M. P., Nardone, V., D’Onofrio, I., Pirozzi, M., Sandomenico, F., Farese, S., Chiara, M. D., Balbo, C., Cappabianca, S., & Fasano, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092080 · Cited by 14

Microenvironment-based immunotherapy in oral cancer: a comprehensive review

Mivehchi, H., Eskandari-Yaghbastlo, A., Ghazanfarpour, M., Ziaei, S., Mesgari, H., Faghihinia, F., Ashtiani, N. Z., & Nabi‐Afjadi, M. (2025) · Medical Oncology · doi:10.1007/s12032-025-02694-5 · Cited by 15

miR-3187-3p enhances migration and invasion by targeting PER2 in head and neck squamous cell carcinomas

Xiao, L., Liu, C., Zhang, S., Qiu, Y., Huang, D., Zhang, D., Chen, H., Ling, H. H., Liu, Y., & Zhang, X. (2021) · Journal of Cancer · doi:10.7150/jca.58593 · Cited by 14

Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold

Turchan, W. T., Pitroda, S. P., & Weichselbaum, R. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179573 · Cited by 14

Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck

Otsuki, S., Hori, R., Shinohara, S., Kojima, T., Tamaki, H., Asato, R., Kitamura, M., Ichimaru, K., Kitani, Y., Kumabe, Y., et al. (2022) · Auris Nasus Larynx · doi:10.1016/j.anl.2022.02.006 · Cited by 14

Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review

Dar, T. B., Biteghe, F. A. N., Kakar, R., Aniogo, E. C., Malindi, Z., Akinrinmade, O. A., Chalomie, N. E. T., Kombe, A. J. K., Angone, S. A., Ndong, J. M. N., et al. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02888-7 · Cited by 14

True abscopal effect in a patient with metastatic non-small cell lung cancer

Vilinovszki, O., Andratschke, N. H., Huellner, M. W., Fontecedro, A. C., & Kroeze, S. G. C. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01920-4 · Cited by 14

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis

Liu, Z., Xu, T., Chang, P., Fu, W., Wei, J., Xia, C., Wang, Q., Li, M., Pu, X., Huang, F., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1064227 · Cited by 13

Effect of time‐of‐day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma: A secondary analysis of a prospective randomized trial

Janopaul-Naylor, J. R., Boe, L. A., Yu, Y., Sherman, E. J., Pfister, D. G., Lee, N. Y., & McBride, S. M. (2024) · Head & Neck · doi:10.1002/hed.27825 · Cited by 13

Antiangiogenic Treatment Facilitates the Abscopal Effect of Radiation Therapy Combined With Anti-PD-1 in Hepatocellular Carcinoma

Sheng, H., Luo, Y., Zhong, D. L., Wang, Z., Sun, Z., Gao, X., He, M. X., Zhu, Z., Wu, D. D., Sun, D. J., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.09.024 · Cited by 13

Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition

Akama‐Garren, E. H., Morris, Z. S., Sikora, A. G., Weichselbaum, R. R., & Schoenfeld, J. D. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.08.009 · Cited by 13

A cuproptosis and copper metabolism–related gene prognostic index for head and neck squamous cell carcinoma

Zhang, S., Zhang, L., Lu, H., Yao, Y., Liu, X., & Hou, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955336 · Cited by 13

Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma

Zhou, X., & Wang, X. (2022) · Biomedicines · doi:10.3390/biomedicines10081990 · Cited by 12

Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer

Xue, H., Chen, Y., & Zhou, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1522508 · Cited by 12

Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer?

Wilkins, A. C., Ost, P., & Sundahl, N. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.02.014 · Cited by 13

Targeting Intratumoral Copper Inhibits Tumor Progression via p62‐Mediated EZH2 Degradation and Potentiates Anti‐PD‐1 Immunotherapy in Oral Squamous Cell Carcinoma

Lin, X., Chen, W., Li, B., Zhang, Z., Yu, Z., Zhao, X., Zhou, X., Feng, Z., Lin, C., & Cao, W. (2025) · Advanced Science · doi:10.1002/advs.202417795 · Cited by 11

Survival, Treatment Outcome, and Safety of Multiple and Repeated Courses of Stereotactic Body Radiotherapy for Pulmonary Oligometastases of Head and Neck Squamous Cell Carcinoma

Vorbach, S. M., Mangesius, J., Dejaco, D., Seppi, T., Santer, M., Nedden, S. Z., Sarcletti, M., Pointner, M., Hart, T., Riechelmann, H., et al. (2023) · Cancers · doi:10.3390/cancers15215253 · Cited by 11

RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy

Wang, L., Katipally, R. R., Liang, H. L., Yang, K., Pitroda, S. P., He, C., & Weichselbaum, R. R. (2023) · Med · doi:10.1016/j.medj.2023.09.001 · Cited by 11

Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review

Li, J., Luo, Z., Jiang, S., & Li, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112200 · Cited by 12

A Randomized, Multicenter, Phase 2 Trial of Camrelizumab With or Without Metastasis-directed Stereotactic Body Radiation Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma

Zhang, X., Jin, Y., Lei, Q., Neo, J., Tan, S. H., Shu, X., Huang, L., Long, B., Xie, Y., Wang, F., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.10.019 · Cited by 12

PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report

Xu, H. L., Hong, Z., Xu, M., Kong, Y., Ma, Y., Shan, C., Xing, P., & Zhang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.926740 · Cited by 11

Modeling of radiation effects to immune system: a review

Sung, W., & Cho, B. (2022) · Journal of the Korean Physical Society · doi:10.1007/s40042-022-00574-z · Cited by 12

Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes

Figura, N. B., Sim, A. J., Jain, M. D., Chávez, J. C., & Robinson, T. J. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2147919 · Cited by 11

The abscopal effect and its implications for radiotherapy-immunotherapy combinations

Rowell, N. P. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2354 · Cited by 14

Targeting the mitochondrial calcium uniporter inhibits cancer progression and alleviates cisplatin resistance in esophageal squamous cell carcinoma

Miao, Y., Wang, X., Lai, Y., Huang, Y., Yin, H., Meng, X., Liu, H., Hou, R., Lin, W., Zhang, X., et al. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5530 · Cited by 11

The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond

Onderdonk, B. E., & Chmura, S. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00706 · Cited by 11

Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial

Tang, J. P., Yang, Y., Liu, D., Wang, B., Lin, Z., Wu, Z., Zhang, J., Zhang, D., Liu, Y., Ge, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67528-4 · Cited by 11

Clinical Efficacy of Immune Checkpoint Inhibitors in Patients with Brain Metastases

Nunno, V. D., Nuvola, G., Mosca, M., Maggio, I., Gatto, L., Tosoni, A., Lodi, R., Franceschi, E., & Brandes, A. A. (2021) · Immunotherapy · doi:10.2217/imt-2020-0208 · Cited by 10

Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma

Lim, A. M. L., Cavanagh, K., Hicks, R. J., McLean, L. S., Goh, M., Webb, A., & Rischin, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656611 · Cited by 10

A multi-institutional analysis of outcomes following stereotactic body radiation therapy for management of metastases from squamous cell carcinomas of the head and neck.

Singh, R. B., Jenkins, J., Davis, J. N., Song, S., Sharma, S. K., & Vargo, J. A. (2022) · PubMed Central · Cited by 10

Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case Study

Anzellini, D., Sanctis, V. D., Valeriani, M., Reverberi, C., Marinelli, L., Massaro, M. M., Vullo, G., Facondo, G., Sigillo, R. C., Tosi, E., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15327 · Cited by 9

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis

Tang, Q., Wu, D., Huang, H., Fang, H., Wu, Y., Liu, F., & Li, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1093194 · Cited by 9

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review

Mireștean, C. C., Stan, M. C., Schenker, M., Volovat, C. D., Volovăț, S. R., Iancu, D. T., Iancu, R. I., & Bădulescu, F. (2023) · Diagnostics · doi:10.3390/diagnostics13162620 · Cited by 9

A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma

Li, L., Chen, L., Fan, M., Tian, Y., Ai, H., Lu, Y., Fang, L., Lan, M., Lai, X., Huang, Y., et al. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.106695 · Cited by 9

A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).

McBride, S. M., Sherman, E. J., Tsai, C. J., Baxi, S. S., Aghalar, J., Eng, J., Zhi, W. I., McFarland, D. C., Michel, L. S., Spielsinger, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6009 · Cited by 61

CAMRESBRT: Randomized Phase II Trial of Camrelizumab with Stereotactic Body Radiotherapy vs. Camrelizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Lei, Q., Wang, Y., Sui, J.-D., Luo, Q., Jin, F., Long, B., Shu, X., Li, S., Huang, L., Zhong, M., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.1302

The Abscopal Effect in Head-and-Neck Squamous Cell Carcinoma Treated with Radiotherapy and Nivolumab: A Case Report and Literature Review

Forner, D. W. A., Horwich, P., Trites, J. R. B., Hollenhorst, H., Bullock, M. J., & Lamond, N. W. D. (2020) · Current Oncology · doi:10.3747/co.27.6687 · Cited by 25

A randomized phase II study of chemoradiation (CRT) +/- nivolumab (Nivo) with sequential safety evaluations of Nivo +/- lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).

Gillison, M. L., Ferris, R. L., Zhang, Q., Colevas, A. D., Mell, L. K., Kong, C. S., Jordan, R. C., Moore, K. L., Truong, M. T., Kirsch, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps6097 · Cited by 4

Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

Gillison, M. L., Ferris, R. L., Zhang, Q., Colevas, A. D., Mell, L. K., Kirsch, C., Moore, K. L., Truong, M. T., Kong, C. S., Jordan, R., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.12.022 · Cited by 11